"When links are tightened between biomedical research and clinical practice, results are quick and often spectacular for the patients, who can thus benefit from healthcare adapted to the specificities of their disease."

Henri Bounameaux, Dean, UNIGE Faculty of Medicine

Cancer is one of the leading causes of death in Switzerland with nearly 15,000 victims yearly. It affects particularly people of working age, where it causes about 45% of deaths among men and more than 60% of women between the ages of 30 and 65.

Geneva has state-of-the-art expertise in oncology:  at the Geneva University Hospitals (HUG), where the “Fondation Dr Henri Dubois-Ferrière Dinu Lipatti Clincial Research Unit in Oncohaematology” grants access to innovating drugs not yet available outside of clinical trials; and at the other end of the innovation chain, at the UNIGE Faculty of Medicine, which has exceptional research laboratories working on genetic and cellular mechanisms that cause tumours.

To rally all researchers’ talent in a common identity, the Translational Research Centre in Onco-haematology (CRTOH) was made possible, thanks to a public-private partnership that brings together the UNIGE Faculty of Medicine, the HUG, as well as an exceptional consortium of five private foundations. Their common goal is to translate as quickly as possible the discoveries of biomedical sciences into effective treatments.

The CRTOH is part of the Swiss Cancer Centre - Leman (SCCL), in collaboration with the HUG, EPFL, CHUV, UNIL and the ISREC Foundation.